Global Next-Generation Antibody Therapies Market Forecast 2018-2028 - Visiongain Report

LONDON, October 2, 2018 /PRNewswire/ --

Antibody-Drug Conjugates, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments & ALPs, Biosimilar Antibodies 

The global next-generation antibody therapies market reached $4bn in 2017 and is estimated to reach $17bn by 2023. In 2017, the antibody-drug conjugates segment held 45% of the global next-generation antibody therapies market.

     (Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 217-page report you will receive 141 charts- all unavailable elsewhere.

The 217-page report provides clear detailed insight into the next-generation antibody therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• Global Next-Generation Antibody Therapies Market from 2018-2028

• Forecast of the Global Next-Generation Antibody Therapies market by Submarket:
• Antibody Fragments & ALPs
• Antibody-Drug Conjugates
• Biosimilar Antibodies
• Bispecific Antibodies
• Engineered Antibodies

• Forecast of the Global Antibody Fragments & ALPs submarket by Product:
• Kalbitor
• Other Antibody Fragments

• Forecast of the Global Antibody-Drug Conjugates submarket by Product:
• Adcetris
• Kadcyla
• Mylotarg
• Other ADCs

• Forecast of the Global Biosimilar Antibodies submarket by Product:
• Infliximab
• Adalimumab
• Rituximab
• Bevacizumab
• Trastuzumab
• Other Biosimilar mAbs

• Forecast of the Global Bispecific Antibodies submarket by Product:
• Blincyto
• Hemlibra
• Other Bispecific Antibodies

• Forecast of the Global Engineered Antibodies submarket by Product:
• Gazyva/Gazyvaro
• Poteligeo
• Fasenra
• Other Engineered Antibodies

• This report provides individual revenue forecasts to 2028 for these regional and national markets:
• North America: US, Canada, and Mexico
• Europe: Germany, France, United Kingdom, Italy, Spain, Russia, and rest of Europe
• Asia-Pacific: Japan, China, Australia, South Korea, India, and rest of Asia-Pacific
• LAMEA: Brazil, Saudi Arabia, Republic of South Africa, Turkey, and rest of LAMEA

• Our study discusses the selected leading companies that are the major players in the next-generation antibody therapies market:
• Amgen, Inc.
• GlaxoSmithKline (GSK)
• Kirin Holdings (Kyowa Hakko Kirin Co., Ltd.)
• Merck KGaA
• Novartis AG
• Pfizer, Inc.
• Roche
• Sanofi
• Seattle Genetics, Inc.
• Shire plc

• This report discusses SWOT & STEP analysis of the next-generation antibody therapies market as well as factors that drive and restrain this market. This report also discusses the opportunities that can be tapped in this market.

• This report also discusses selected at that are in the pipeline.

Visiongain's study is intended for anyone requiring commercial analyses for the next-generation antibody therapies market. You find data, trends and predictions.

Buy our report today Global Next-Generation Antibody Therapies Market Forecast 2018-2028: Antibody-Drug Conjugates, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments & ALPs, Biosimilar Antibodies

To request a report overview of this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/global-next-generation-antibody-therapies-market-forecast-2018-2028/

AbbVie
AbGenomics
Ablynx
AdAlta
ADC Therapeutics
Adnexus
Affimed Therapeutics
Agensys
Alcon
Alexion
Algeta ASA
Allergan
ALMAC Group
Ambrx
Amgen
arGEN-X
Astellas Pharma
AstraZeneca
Bayer
Biogen Idec
BioNet Ventures
Biotest
BioWa
Boehringer Ingelheim
Bristol-Myers Squibb
Cancer Drugs Fund
CARBOGEN AMCIS
Cascadian Therapeutics, Inc.
Catalent Pharma Solutions
Celgene
Celldex Therapeutics
Cephalon
Cilag GmbH International
Clovis Oncology
Coldstream Laboratories
Concortis Biosystems
Corixa
Covagen
Crescendo Biologics
CSL Behring
CVie Therapeutics
CytomX Therapeutics
Daiichi Sankyo
Defiante Farmaceutica
Delenex Therapeutics
Domantis
Dutalys
Dyax
Eddingpharm
Eisai
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
ESBATech
Esperance Pharmaceuticals
ETH Zurich
FDA
Five Prime Therapeutics
Formation Biologics
Fresenius Biotech
F-Star
Fujifilm
Genentech
Genmab
Gilead Sciences
Glenmark
Glycart
Glycotope
Goodwin Biotechnology
GSK
Health Canada
Igenica
Immune Design
Immunocore
ImmunoGen
Immunomedics
IONTAS
Janssen Biotech
Jazz Pharmaceuticals
Kalobios
Karolinska Institute
Kyowa Hakko Kirin
Kyowa Medex
LINDIS Biotech
Lonza
MacroGenics
MedImmune
Merck
Merrimack Pharmaceuticals
Mersana Therapeutics
Merus
Micromet
Millennium Pharmaceuticals
Molecular Partners
MorphoSys
MultiCell Immunotherapeutics (MCIT)
National Institute of Diabetes and Digestive and Kidney Diseases
Neopharm
Neovii Biotech
Nerviano Medical Sciences
NHS
NICE
NMS Group
Nordic Nanovector ASA
Novartis
Novartis Institutes for BioMedical Research (NIBR)
NovImmune
Oxford BioTherapeutics
Oxis Biotech
Pfizer
Pharmacyclics
Pieris
Piramal Enterprises
Piramal Healthcare
PolyTherics
ProBioGen
Progenics
ProStrakan
Redwood BioScience
Roche
Salix
Sanofi
Scil Proteins
Seattle Genetics
Servier
Shinogi
Shire
Sigma-Tau
Simcere Pharmaceutical Group
Sorrento Therapeutics
Spectrum Pharmaceuticals
Spirogen
Stelis Biopharma
Stemcentrx
Strides Arcolab
Sutro Biopharma
Swedish Orphan Biovitrum (Sobi)
Swiss Federal Institute of Technology
Synthon
Synthon Biopharmaceuticals
Takeda
Talon Therapeutics
Teva
TG Therapeutics
The American Society of Hematology
The University of Texas MD Anderson Cancer Center
TRION Pharma
UCB
WHO
Wyeth
Xencor
Zydus Cadila
Zymeworks

To see a report overview please e-mail Sara Peerun on [email protected]

SOURCE Visiongain